

Press Release

For Immediate Release

Glenmark becomes the First Pharmaceutical Company to launch Indacaterol + Mometasone Fixed-Dose Combination Drug for Asthma in India

- *The novel fixed-dose combination will help in the management of uncontrolled asthma by improving lung function, better symptom control and reducing exacerbations.*
- *Glenmark is the first company in India to market the innovative FDC of Indacaterol, a long-acting beta-agonist and Mometasone, an inhaled corticosteroid which is approved by the Indian Drug Regulator.*
- *Launched under the brand name Indamet[®], the drug will increase the accessibility of quality drugs for effective asthma management.*
- *Indamet[®] will be available in three strengths: 150 mcg/80, 160 and 320 mcg.*

Mumbai, June 16, 2022: Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven global pharmaceutical company has launched the novel fixed-dose combination (FDC) drug - Indacaterol + Mometasone for patients suffering from uncontrolled asthma, in India. The company has launched this FDC under the brand name Indamet[®]. The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg, and 320 mcg respectively, to be taken once daily.

While speaking on the development, Alok Malik, Group Vice President & Head, India Formulations – Glenmark Pharmaceuticals Ltd. said, “Respiratory is a key focus area for Glenmark and the company leads from the front in providing access to the latest treatment options to patients. We are proud to introduce this novel fixed-dose combination Indamet[®], which is the first of its kind in India; offering a world-class and affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma.”

Glenmark is the first company in India to market the innovative FDC of Indacaterol, a long-acting beta-agonist and Mometasone Furoate, an inhaled corticosteroid which is approved by the DCGI (Drug Controller General of India).

Asthma is a major non-communicable disease (NCD), affecting both children and adults caused due to inflammation and narrowing of the small airways in the lungs. Asthma affects more than 34 million people in India, causing thousands of deaths every yearⁱ. According to the Global Burden of Disease report by the Institute for Health Metrics and Evaluation (IHME), asthma accounted for 27.9% of disability-adjusted life years (DALYs) in Indians causing 3 times higher mortality and 2 times higher DALYs compared to the global proportion of asthma. Out of the total asthmatic patients undergoing conventional treatment in India, up to 49% have uncontrolled asthmaⁱⁱ. Indamet[®] will help in the management of uncontrolled asthma by improving lung function, better symptom control and reducing exacerbations.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark is ranked among the world's top 100 biopharmaceutical companies (Top 100 Companies Ranked by Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the world's top 50 companies in the off-patent sector (Top 50 Generics and Biosimilars Companies ranked by Sales, 2020, by Generics Bulletin/In Vivo). The company was listed on the Dow Jones Sustainability Index (DJSI), one of the world's most respected and widely accepted sustainability benchmarks, under the category of emerging markets (2021) for the fourth consecutive year in a row. For more information, visit www.glenmarkpharma.com.

Follow us on Social Media:

LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma)

For more information, please contact

Udaykumar Murthy

DGM, Corporate Communications

+91 9960377617 | corpcomm@glenmarkpharma.com

References

ⁱ <https://openres.ersjournals.com/content/erjor/early/2022/01/20/23120541.00528-2021.full.pdf>

ⁱⁱ Sagadevan S, et al. J. Evolution Med. Dent. Sci. 2019;8(43):3220-3224 3. Jain, N et al. Lung India. 2019 Mar-Apr;36(2):131-138
Buhl R, et al. Respiratory medicine. 2020 Feb 1; 162:105859